MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Search

Bayer AG

Închisă

SectorFinanțe

26.36 -0.17

Rezumat

Modificarea prețului

24h

Curent

Minim

26.185

Maxim

26.425

Indicatori cheie

By Trading Economics

Venit

1.6B

1.3B

Vânzări

2B

14B

P/E

Medie Sector

30.9

24.968

EPS

2.49

Randament dividend

0.44

Marjă de profit

9.492

Angajați

90,885

EBITDA

1.9B

3.6B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+0.53% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.44%

4.18%

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

3.5B

25B

Deschiderea anterioară

26.53

Închiderea anterioară

26.36

Sentimentul știrilor

By Acuity

37%

63%

139 / 538 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Bayer AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 mai 2025, 08:22 UTC

Câștiguri
Principalele dinamici ale pieței

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

13 mai 2025, 06:09 UTC

Câștiguri

Bayer Confirms Guidance Despite Net Profit Drop

24 mar. 2025, 09:37 UTC

Principalele dinamici ale pieței

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 iun. 2025, 08:29 UTC

Market Talk

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30 mai 2025, 13:47 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27 mai 2025, 12:22 UTC

Market Talk
Câștiguri

Bayer's Prospects Are Improving -- Market Talk

16 mai 2025, 13:42 UTC

Acțiuni populare

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mai 2025, 08:57 UTC

Acțiuni populare

Stocks to Watch Friday: Richemont, Bayer, Take-Two, UnitedHealth -- WSJ

15 mai 2025, 22:46 UTC

Top știri
Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

13 mai 2025, 06:50 UTC

Market Talk
Câștiguri

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

13 mai 2025, 05:36 UTC

Câștiguri

Bayer: Sees EBITDA Margin Before Special Items of Pharma Division to Come in at Upper End of Guidance Range

13 mai 2025, 05:35 UTC

Câștiguri

Bayer: Sees Sales Growth of Pharma Division to Come in at Upper End of Guidance Range

13 mai 2025, 05:34 UTC

Câștiguri

Bayer: Currency Adjusted Basis Guidance Includes Impact From Tariffs

13 mai 2025, 05:34 UTC

Câștiguri

Bayer: Considerable Uncertainty Persists Concerning Future Impacts From Tariffs

13 mai 2025, 05:32 UTC

Câștiguri

Bayer 1Q EPS EUR2.49

13 mai 2025, 05:32 UTC

Câștiguri

Analysts Saw 1Q Ebitda Before Special Items at EUR3.82B

13 mai 2025, 05:32 UTC

Câștiguri

Bayer 1Q Ebitda Before Special Items EUR4.085B

13 mai 2025, 05:31 UTC

Câștiguri

Bayer 1Q EBIT EUR2.32B

13 mai 2025, 05:31 UTC

Câștiguri

Bayer 1Q Net Pft EUR1.30B

13 mai 2025, 05:31 UTC

Câștiguri

Analysts Saw Bayer 1Q Net Pft at EUR1.485B

13 mai 2025, 05:30 UTC

Câștiguri

Analysts Saw Bayer 1Q Sales at EUR13.41B

13 mai 2025, 05:30 UTC

Câștiguri

Bayer 1Q Sales EUR13.74B

13 mai 2025, 05:30 UTC

Câștiguri

Bayer Backs 2025 View

14 apr. 2025, 13:00 UTC

Top știri

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7 apr. 2025, 17:01 UTC

Market Talk

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2 apr. 2025, 09:27 UTC

Acțiuni populare

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 mar. 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

Comparație

Modificare preț

Bayer AG Așteptări

Obiectiv de preț

By TipRanks

0.53% sus

Prognoză pe 12 luni

Medie 26.58 EUR  0.53%

Maxim 33 EUR

Minim 20 EUR

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBayer AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

13 ratings

3

Cumpărare

10

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

22.99 / 23.88Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

139 / 538 Clasament în Finanțe

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.